

Bimzelx costs up to $22,000/month without insurance. Learn how to save with copay cards, patient assistance programs, and other strategies.
Bimzelx (Bimekizumab-bkzx) is one of the most effective biologics available for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. It's the only biologic that blocks both IL-17A and IL-17F, and clinical trials have shown it outperforms several older biologics for skin clearance.
But none of that matters if you can't afford it. The cash price of Bimzelx ranges from $16,000 to $22,000 per month without insurance — one of the more expensive biologics on the market. Even with insurance, specialty medication copays can run into the hundreds or thousands of dollars.
The good news? There are real ways to bring that cost down significantly. Here's everything you need to know about saving money on Bimzelx in 2026.
Let's start with the numbers:
There is no generic version of Bimzelx and no biosimilar available. Bimzelx is a newer biologic still under patent protection, so these prices are unlikely to drop significantly in the near term.
The most important savings tool for Bimzelx is the manufacturer's own program. UCB offers the MyNavigate copay card, which can dramatically reduce your out-of-pocket cost:
This is by far the biggest savings opportunity for most patients. If you have commercial insurance, enroll in the MyNavigate program before your first dose.
The program isn't just a discount card. It also provides:
If you're uninsured or underinsured, UCB offers a separate Patient Assistance Program (PAP) that may provide Bimzelx at no cost. Eligibility is typically based on:
Your doctor's office can help you apply, or you can find information through patient assistance databases like:
If your insurance covers Bimzelx, using your plan's preferred specialty pharmacy can reduce copays. Some plans have tiered specialty pharmacy networks where certain pharmacies offer lower out-of-pocket costs. Ask your insurance company which specialty pharmacy they recommend for Bimzelx.
Because Bimzelx is so expensive, it often pushes patients through their deductible and out-of-pocket maximum early in the year. Strategic timing tips:
Some specialty pharmacies and UCB itself may offer bridge or quick-start programs that provide the first dose or two while insurance approval is pending. This ensures you start treatment on time without paying full price out of pocket.
Some states have pharmaceutical assistance programs for residents who need help affording specialty medications. These are especially relevant for patients on Medicare who can't use the manufacturer copay card. Check your state's health department website for details.
Traditional prescription discount cards like GoodRx, SingleCare, and RxSaver are designed primarily for generic medications at retail pharmacies. Because Bimzelx is:
...these discount cards typically offer minimal savings on Bimzelx. The UCB MyNavigate copay card will almost always provide better savings for commercially insured patients. For uninsured patients, the Patient Assistance Program is the better route.
Nobody should have to skip a medication that works because of cost. While Bimzelx has a high list price, the combination of UCB's copay card (as low as $5 per dose), patient assistance programs, and smart insurance strategies can make it affordable for most patients.
Start by enrolling in UCB MyNavigate. Then use Medfinder to find a specialty pharmacy with Bimzelx in stock, and work with your doctor's office to handle insurance approvals.
For help finding Bimzelx, see how to find Bimzelx in stock near you. To understand why it can be hard to access, read why Bimzelx is so hard to find in 2026. And if you're considering other options, check out alternatives to Bimzelx.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.